Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at AA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results